- 6319 Castle Pl #2c, Falls Church, VA 22044
Obesity is a chronic metabolic disease — not a failure of willpower. At Millennium Medical Center, Dr. Shayma, MD approaches weight management as an internal medicine problem: evaluating the metabolic, hormonal, and behavioral drivers of weight, and deploying evidence-based tools including GLP-1 receptor agonists (semaglutide, tirzepatide) for appropriate candidates.
GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — represent the most significant advance in weight management medicine in decades. At Millennium, GLP-1 evaluation is conducted as part of a comprehensive metabolic assessment — not as a prescription-mill transaction. We evaluate insulin resistance, thyroid function, hormonal contributors, and lifestyle factors. Candidacy for GLP-1 medications is determined on clinical grounds.
Weight management at Millennium means a comprehensive metabolic evaluation, physician assessment of your candidacy for GLP-1 medications, managed titration with side effect monitoring, and integration of dietary guidance — not a prescription handed across a telehealth screen with no follow-up.
Berberine activates AMPK and has modest GLP-1 amplifying effects — a reasonable adjunct for patients with mild metabolic dysregulation or those who are not GLP-1 candidates. It is not equivalent to pharmaceutical GLP-1 agonists in efficacy, but has a reasonable evidence base for metabolic support. Dr. Shayma can advise on berberine’s appropriate role in your specific plan.
Dr. Shayma evaluates the full metabolic picture before prescribing any weight management medication — because sustainable weight management requires addressing the full metabolic picture.
01
Complete candidacy evaluation, contraindication screening, prescription management, dose titration, side effect monitoring, and ongoing follow-up for GLP-1 receptor agonist therapy. Semaglutide (Ozempic/Wegovy): ~15% average weight loss. Tirzepatide (Mounjaro/Zepbound): ~20% average weight loss as the most effective approved pharmacological option currently available.
02
Early identification and intervention for insulin resistance and pre-diabetes — before progression to type 2 diabetes. Comprehensive evaluation and management of metabolic syndrome: abdominal obesity, elevated triglycerides, low HDL, hypertension, and insulin resistance — a cluster that dramatically increases cardiovascular risk.
03
Evaluation of hormonal contributors to weight gain: thyroid dysfunction, cortisol excess, testosterone deficiency, and the hormonal changes of perimenopause — with integrated treatment. Evidence-based dietary guidance including protein optimization for GLP-1 patients. Regular follow-up labs and clinical assessment to track progress and adjust medications.
04
Evaluation of hormonal contributors to weight gain including thyroid dysfunction, cortisol excess, testosterone deficiency (in men), and the hormonal changes of perimenopause — with integrated treatment.
GLP-1 medications at Millennium are prescribed after a thorough metabolic evaluation and candidacy assessment. Contraindications (thyroid cancer history, MEN2, pancreatitis history) are screened before prescription. Side effects are monitored and managed throughout treatment.
GLP-1 medications at Millennium are prescribed after a thorough metabolic evaluation and candidacy assessment. Contraindications (thyroid cancer history, MEN2, pancreatitis history) are screened before prescription. Side effects are monitored and managed throughout treatment.
A 45–60 minute comprehensive consultation covering your weight history, prior interventions, dietary patterns, metabolic labs, and health goals. A metabolic workup is ordered, and a personalized weight management plan is developed at your results review appointment.
GLP-1 medications at Millennium are prescribed for appropriate candidates following a thorough evaluation — and patients receive ongoing physician monitoring rather than a prescription with no follow-up. Honest expectations are set from the first visit.
GLP-1 medications are FDA-approved for adults with a BMI of 30 or higher, or BMI of 27 or higher with a weight-related comorbidity (type 2 diabetes, hypertension, high cholesterol, or obstructive sleep apnea).
GLP-1 medications are FDA-approved for adults with a BMI of 30 or higher, or BMI of 27 or higher with a weight-related comorbidity (type 2 diabetes, hypertension, high cholesterol, or obstructive sleep apnea).
Comprehensive metabolic evaluation, ongoing physician monitoring, and evidence-based dietary guidance distinguish Millennium’s weight management from telehealth GLP-1 prescription services.
GLP-1 medications are not recommended for patients with personal or family history of medullary thyroid cancer, MEN2 syndrome, or pancreatitis. Dr. Shayma will be direct about all relevant contraindications at consultation.
Dr. Shayma takes a full history: weight trajectory, prior interventions, dietary patterns, activity level, medications, comorbidities, and your specific goals. This context shapes everything that follows. 45–60 min.
01
Dr. Shayma takes a full history: weight trajectory, prior interventions, dietary patterns, activity level, medications, comorbidities, and your specific goals. This context shapes everything that follows. 45–60 min.
02
A complete metabolic lab panel is ordered: fasting glucose, insulin, HbA1c, lipid panel, thyroid, liver and kidney function, hormonal markers, and inflammatory markers. Labs provide the objective basis for your treatment plan. Results in 1–3 days.
03
Dr. Shayma reviews results, determines GLP-1 candidacy, screens for contraindications, and builds a personalized weight management plan — pharmacotherapy, dietary guidance, and monitoring schedule.
04
GLP-1 medications are started at the lowest dose and titrated according to protocol and your response. Monthly follow-up visits manage side effects, assess progress, and adjust the plan based on actual metabolic outcomes.
The four pillars of medical credibility — and why physician-led Weight & Metabolic Health produces better outcomes than delegated or unmonitored alternatives.
Dr. Shayma manages weight and metabolic health as part of comprehensive internal medicine practice — integrating cardiovascular risk, hormonal contributors, medication effects, and metabolic lab data into a unified treatment approach. Weight management at Millennium is physician-led from start to finish.
As a board-certified internist, Dr. Shayma brings the expertise to evaluate insulin resistance, metabolic syndrome, thyroid dysfunction, hormonal contributors, and cardiovascular risk as an integrated picture — and to prescribe, titrate, and monitor GLP-1 medications with clinical depth that telehealth weight loss services cannot replicate.
Millennium Medical Center provides GLP-1 therapy under the same evidence-based standards applied to all therapeutic interventions: candidacy assessment, contraindication screening, informed consent, dose titration per clinical guidelines, and ongoing monitoring for efficacy and safety.
Dr. Shayma does not operate as a prescription mill. GLP-1 medications are prescribed for appropriate candidates following a thorough evaluation — and patients receive ongoing physician monitoring rather than being handed a prescription and left to manage alone.
The most common questions patients ask about weight management and GLP-1 medications at Millennium Medical Center.
GLP-1 receptor agonists are FDA-approved for adults with a BMI of 30 or higher, or BMI of 27 or higher with a weight-related comorbidity. A physician evaluation is required to determine candidacy and rule out contraindications including personal or family history of thyroid cancer, MEN2 syndrome, or pancreatitis.
In clinical trials, semaglutide (Wegovy) produced an average weight loss of approximately 15% of body weight over 68 weeks. Individual results vary based on dose, adherence, diet, and activity. Most patients begin to see meaningful weight loss at 8–12 weeks as the dose is titrated up.
Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes management and comes in doses up to 2 mg. Wegovy is FDA-approved specifically for chronic weight management and comes in doses up to 2.4 mg. The prescribing rationale depends on your clinical indication and insurance coverage.
The most common side effects are gastrointestinal: nausea, vomiting, constipation, and diarrhea — particularly during dose escalation. Most improve as the body adjusts. Starting at the lowest dose and titrating slowly significantly reduces side effect severity.
Clinical trial data shows that most patients regain a significant portion of lost weight when GLP-1 medications are discontinued — reinforcing the view of obesity as a chronic condition requiring ongoing management. Dr. Shayma discusses long-term management expectations from the first visit.
Begin Your Journey
Whether you are coming in for internal medicine, aesthetic care, or to explore a physician-led treatment plan built around your health — Millennium Medical Center is ready to see you. Book your consultation today and experience care that starts from within.
